Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belantamab mafodotin + feladilimab
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Belantamab mafodotin + feladilimab** is an investigational combination therapy for relapsed/refractory multiple myeloma. Belantamab mafodotin is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), delivering the cytotoxin monomethyl auristatin F (MMAF) into BCMA-expressing myeloma cells to induce apoptosis. Feladilimab is a monoclonal antibody targeting the Inducible T-cell COStimulator (ICOS), a costimulatory immune receptor, and acts as an agonist to enhance T-cell activation. This combination aims to exploit both direct anti-tumor cytotoxicity (via the ADC) and immune-mediated anti-myeloma activity (via ICOS agonism)[5]. The agents are being studied together in platform trials such as DREAMM-5, developed and sponsored by GSK, for patients with relapsed/refractory multiple myeloma after prior therapies[5].
02
Targets
BCMA (B-cell maturation antigen)ICOS (Inducible T-cell costimulator)
Beyond the preview
Go deeper on belantamab mafodotin + feladilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belantamab mafodotin + feladilimab.